This HTML5 document contains 80 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n8http://dx.doi.org/10.1182/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q90007363
rdf:type
wikibase:Item
schema:description
2018 թվականի հուլիսի 12-ին հրատարակված գիտական հոդված wetenschappelijk artikel artículu científicu espublizáu en xunetu de 2018 наукова стаття, опублікована в липні 2018 scientific article published on 12 July 2018
p:P577
wds:Q90007363-71CC3849-7A0E-4BE7-808F-E213F363EC50
wdt:P577
2018-07-12T00:00:00Z
p:P2093
wds:Q90007363-8166CDC3-59E0-4DF0-9D10-962C4AFF0999 wds:Q90007363-CE1A9220-9C99-4433-8576-F61A5C90B2ED wds:Q90007363-910BF7FC-EBB7-4975-BE2E-D65266134119 wds:Q90007363-414E3045-A984-4B1D-9AE7-6BF4673E0797
wdt:P2093
Doris Barcellona Maria Gerosa Anna Falanga Caterina Cenci
rdfs:label
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
skos:prefLabel
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
schema:name
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
p:P50
wds:Q90007363-F7627C87-C27B-46E0-8890-E54B6A351CAD wds:Q90007363-BA1F7B18-E032-48A0-A8DF-2086F2DF9B01 wds:Q90007363-C2589709-C385-4E0C-91D5-E038D33A1204 wds:Q90007363-DE39A0CE-FB05-45F2-87A6-F54FACF49F50 wds:Q90007363-E447F244-32FF-4864-98A7-394BC4F029F5 wds:Q90007363-E8153B21-932E-48CA-90B6-41279A14E805 wds:Q90007363-A97F9AD4-C2A4-4927-AB99-3ABA048B0EF0 wds:Q90007363-A98BBC72-6355-4E84-A002-33F81119025A wds:Q90007363-787FC2A1-41CA-4BAA-8170-AD95D9DAE063 wds:Q90007363-8A99BE52-9859-4EB8-A241-2584110A3CDF wds:Q90007363-6505C7D0-ABB9-4224-8966-649F5805AAA3 wds:Q90007363-6F126774-6291-43BA-A1AE-846ABC375C52 wds:Q90007363-3EB93097-1BFB-4081-ACDD-FDF172CBEB17 wds:Q90007363-40BC43D0-2E74-4BBA-AC61-7DDE85819C6D wds:Q90007363-4C583BDD-EEBE-4676-9C46-9AE822673DBE wds:Q90007363-278AD940-C909-4BC4-83C9-657CD62EE998 wds:Q90007363-27F4E6BD-C845-4D1B-AD36-1A6F929D46C2 wds:Q90007363-2478E623-5E96-4E6A-B494-4F651C8E6BA5
wdt:P50
wd:Q57070774 wd:Q60441792 wd:Q92104506 wd:Q73304219 wd:Q114416255 wd:Q93203205 wd:Q114430400 wd:Q114515261 wd:Q95628344 wd:Q42778559 wd:Q114515263 wd:Q43281338 wd:Q46061069 wd:Q38544398 wd:Q61806166 wd:Q56954174 wd:Q114515259 wd:Q37834337
p:P1476
wds:Q90007363-E1AAE51E-EB30-4B0D-B51F-9E08C93027E7
wdt:P1476
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
p:P304
wds:Q90007363-1AB34D9D-651B-4981-B358-EBB107BF96EE
wdt:P304
1365-1371
p:P31
wds:Q90007363-3B4ACCA3-5556-47E4-BA66-832216F7C62E
wdt:P31
wd:Q13442814
p:P921
wds:Q90007363-983A7BA1-5488-427D-92FB-DE7EF5000B94 wds:Q90007363-38E7415D-77AF-4705-B16D-B30778F4F1CA
wdt:P921
wd:Q582207 wd:Q407431
p:P698
wds:Q90007363-27760779-334D-49D1-8092-5A64CBE20C22
wdtn:P698
n9:30002145
wdt:P698
30002145
p:P1433
wds:Q90007363-779C7475-E19F-427A-A160-100139950A41
wdt:P1433
wd:Q885070
p:P433
wds:Q90007363-D04284A5-C4F7-4D6C-8051-D76B16D5BC3E
p:P478
wds:Q90007363-88D3AEF0-DFD3-4369-A42D-1CE88585F04E
wdt:P433
13
wdt:P478
132
p:P356
wds:Q90007363-EF21C72C-2D6F-4C2A-83D6-8A15EC88434F
wdtn:P356
n8:BLOOD-2018-04-848333
wdt:P356
10.1182/BLOOD-2018-04-848333